Haemodynamic augmentation in the treatment of vasospasm in aneurysmal subarachnoid hemorrhage
- PMID: 22843460
- DOI: 10.5137/1019-5149.JTN.3863-10.1
Haemodynamic augmentation in the treatment of vasospasm in aneurysmal subarachnoid hemorrhage
Abstract
Aim: Hypertension, hypervolemia and hemodilution therapy is a common approach to cerebral vasospasm after subarachnoid haemorrhage. This study is designed to see the difference of moderate or aggressive hypervolemia supported with induced hypertension in symptomatic vasospasm detected with transcranial Doppler ultrasonography (TCD) measurements.
Material and methods: Fifty eight patients who had aneurysm clipping and were admitted to the neurointensive care unit were treated with normovolemia and induced hypertension (n=35) or hypervolemia supported with induced hypertension (n=23) targeting a mean arterial pressure of 110-130 mm Hg and central venous pressure of 8-12 mm Hg. Daily TCD, fluid intake, fluid balance and haemodynamic values were recorded for 14 days.
Results: There were no differences detected in mean arterial pressure, central venous pressure, hematocrit values, fluid balance and middle cerebral artery flow velocities between the two groups through 14 days (p > 0.05). Hyponatremia, pulmonary edema and cerebral ischemia were observed as complications.
Conclusion: Hypervolemia adds no benefit compared to normovolemia in the treatment of vasospasm occurred as a result of subarachnoid hemorrhage. Induced hypertension establishes the haemodynamic augmentation to prevent and treat vasospasm.
Similar articles
-
Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage.Crit Care Med. 2007 Aug;35(8):1844-51; quiz 1852. doi: 10.1097/01.CCM.0000275392.08410.DD. Crit Care Med. 2007. PMID: 17581487 Clinical Trial.
-
Computational modeling of HHH therapy and impact of blood pressure and hematocrit.World Neurosurg. 2010 Aug-Sep;74(2-3):294-6. doi: 10.1016/j.wneu.2010.02.059. World Neurosurg. 2010. PMID: 21492563
-
Role of transcranial Doppler in optimizing treatment of cerebral vasospasm in subarachnoid hemorrhage.J Intensive Care Med. 2008 Jul-Aug;23(4):263-7. doi: 10.1177/0885066608318516. Epub 2008 May 13. J Intensive Care Med. 2008. PMID: 18480082
-
"Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage.Neurocrit Care. 2006;4(1):68-76. doi: 10.1385/NCC:4:1:068. Neurocrit Care. 2006. PMID: 16498198 Review.
-
Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage.Lancet Neurol. 2003 Oct;2(10):614-21. doi: 10.1016/s1474-4422(03)00531-3. Lancet Neurol. 2003. PMID: 14505583 Review.
Cited by
-
Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review.Br J Anaesth. 2016 Jul;117(1):17-40. doi: 10.1093/bja/aew095. Epub 2016 May 8. Br J Anaesth. 2016. PMID: 27160932 Free PMC article.
-
Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage.Neurocrit Care. 2023 Aug;39(1):1-28. doi: 10.1007/s12028-023-01713-5. Epub 2023 May 18. Neurocrit Care. 2023. PMID: 37202712
-
Hemodynamic Management in the Prevention and Treatment of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.Neurocrit Care. 2023 Aug;39(1):81-90. doi: 10.1007/s12028-023-01738-w. Epub 2023 May 9. Neurocrit Care. 2023. PMID: 37160848 Review.
-
Fluid management of the neurological patient: a concise review.Crit Care. 2016 May 31;20(1):126. doi: 10.1186/s13054-016-1309-2. Crit Care. 2016. PMID: 27240859 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources